Analyst Ratings For Regeneron Pharmaceuticals (NASDAQ:REGN)
Today, BTIG Research reiterated its Hold rating on Regeneron Pharmaceuticals (NASDAQ:REGN).
Some recent analyst ratings include
- 2/13/2018-BTIG Research Reiterated Rating of Hold.
- 2/9/2018-Robert W. Baird Upgrade from a “Neutral ” rating to a ” Outperform” rating.
- 2/8/2018-Jefferies Group Reiterated Rating of Neutral .
Recent Insider Trading Activity For Regeneron Pharmaceuticals (NASDAQ:REGN)
Regeneron Pharmaceuticals (NASDAQ:REGN) has insider ownership of 10.80% and institutional ownership of 65.89%.
- On 10/5/2017 Michael S Brown, Director, sold 1,500 with an average share price of $475.00 per share and the total transaction amounting to $712,500.00.
- On 9/29/2017 Charles A Baker, Director, sold 2,000 with an average share price of $450.00 per share and the total transaction amounting to $900,000.00.
- On 9/6/2017 Robert E Landry, SVP, sold 663 with an average share price of $498.60 per share and the total transaction amounting to $330,571.80.
- On 9/5/2017 Robert E Landry, CFO, sold 189 with an average share price of $501.06 per share and the total transaction amounting to $94,700.34.
- On 8/31/2017 Robert E Landry, SVP, sold 427 with an average share price of $493.43 per share and the total transaction amounting to $210,694.61.
- On 8/25/2017 Sanofi, Major Shareholder, bought 72,378 with an average share price of $481.36 per share and the total transaction amounting to $34,839,874.08.
- On 8/24/2017 Sanofi, Major Shareholder, bought 166,415 with an average share price of $480.93 per share and the total transaction amounting to $80,033,965.95.
Recent Trading Activity for Regeneron Pharmaceuticals (NASDAQ:REGN)
Shares of Regeneron Pharmaceuticals closed the previous trading session at 324.77 down -17.90 5.22% with 324.6099853515625 shares trading hands.